RELL

Richardson is a niche engineered-solutions and power/microwave-tube manufacturer whose numbers tell a clear cyclical story: revenue peaked at $263M in FY2023 with $22.3M of net income, fell to $196M in FY2024 as earnings collapsed to $61K, and has begun recovering to $209M in FY2025 (+6.3%). But the recovery is top-line only — FY2025 swung to a $1.14M net loss and a -$2.46M operating loss (-1.2% margin). A meaningful chunk of that red ink is one-time: the January 2025 sale of the Healthcare business to DirectMed drove a $5.1M loss for the year, so underlying operations are closer to breakeven than the headline suggests, and the accompanying 10-year Siemens CT-tube supply agreement preserves a recurring revenue stream. Gross margin held at a healthy 31.0% (gross profit +8.1%), which argues the loss is about operating deleverage and a divestiture charge, not pricing erosion.

The balance sheet is the anchor to the whole call and the reason this is a hold rather than an avoid despite the loss. Liabilities/equity is just 0.25x, cash rose 48% to $35.9M, current assets of $166M dwarf $36.8M of current liabilities (~4.5x current ratio), and operating cash flow jumped 61.7% to $10.6M — comfortably covering the $3.41M dividend and $2.81M of capex. This is a debt-light, cash-generative business that can fund its ~1.7% dividend and reinvest through a down cycle without stress. Equity of $157M against a $204M market cap puts the stock around 1.3x book and P/S at 1.0.